Trial · NCT06987097
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The primary efficacy endpoint is the composite of pulmonary hypertension progression at 12 months | baseline,12 months | defined as meeting any of the following criteria within 12 months: 1. mPAP ≥ 25 mmHg OR PVR \> 3 WUs as measured by RHC OR 2. worsening of risk stratification compared to baseline, defining as at least one class progression based on the simplified four-tier model of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension |
| Secondary | systolic PAP (sPAP) by Hemodynamic measurements | baseline,12 months | |
| Secondary | mPAP by Hemodynamic measurements | baseline,12 months | |
| Secondary | cardiac output (CO) by Hemodynamic measurements | baseline,12 months | |
| Secondary | cardiac index (CI) by Hemodynamic measurements | baseline,12 months | |
| Secondary | PVR by Hemodynamic measurements | baseline,12 months | |
| Secondary | PVRi by Hemodynamic measurements | baseline,12 months | |
| Secondary | PAWP by Hemodynamic measurements | baseline,12 months | |
| Secondary | right atrial pressure by Hemodynamic measurements | baseline,12 months | |
| Secondary | pulmonary arterial compliance by Hemodynamic measurements | baseline,12 months | |
| Secondary | diameter of chambers by Echocardiographic measurements | baseline,12 months | |
| Secondary | ejection fraction by Echocardiographic measurements | baseline,12 months | |
| Secondary | right ventricular (RV) fraction of area change (FAC) by Echocardiographic measurements | baseline,12 months | |
| Secondary | TAPSE by Echocardiographic measurements | baseline,12 months | |
| Secondary | pulmonary artery accelation time (PAAT) by Echocardiographic measurements | baseline,12 months | |
| Secondary | regurgitation of tricuspid or pulmonary valve by Echocardiographic measurements | baseline,12 months | |
| Secondary | sPAP by Echocardiographic measurements | baseline,12 months | |
| Secondary | RAP by Echocardiographic measurements | baseline,12 months | |
| Secondary | WHO functional class through follow - up | baseline,12 months | |
| Secondary | Borg index through follow - up | baseline,12 months |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06987097/registered